For decades, the pharmaceutical industry was defined by "Eroom’s Law", the observation that drug discovery has become exponentially slower and more expensive over time. Bringing a single drug to market costs up to ~USD3bn and involves a 10 to 15-year development cycle. Despite significant R&D spending, the industry faces an overall ~10% drug approval rate from phase 1 of clinical trials to market approval.
Today, drug discovery still relies heavily on wet labs, where scientists manually test chemicals in petri dishes and on living tissue. Quantum computing represents a historic shift, moving the industry to computational certainty by simulating how a drug will interact with our bodies before any physical testing begins, potentially reducing timeframes.
While modern computers are powerful, they remain limited to simplified approximations of biological complexity. The fundamental difference between traditional hardware and quantum computing is how they evaluate data and complexity. Classical computers are linear; they analyse variables individually in sequence, however biological interactions involve an immense number of possibilities, making this approach limiting. In contrast, quantum computers can evaluate every potential outcome simultaneously. By processing an entire range of possibilities at once, they can map biological interactions with a level of precision that traditional hardware cannot achieve. This shifts drug discovery from sequential experimentation toward a model of computational certainty. Another limitation of classical computers is that they rely on math to describe biology. To simulate the chemical reactions inside a single living molecule with precision would require the power of 1021 GPUs, effectively much more than currently exists. Quantum computing is different in that it uses natural particles that operate on the same physical principles as the molecules being studied. Instead of calculating a result through equations, the system acts out the biological process naturally. This replaces slow mathematical modelling with a high-speed, exact physical simulation.
This computational evolution allows researchers to stress-test drug efficacy and toxicity in a digital environment before committing to physical trials. By moving the failure point of a drug from expensive clinical trials to a low-cost digital simulation, the industry can fundamentally invert the economics of R&D. As the barriers to high-precision simulation fall and the cost of discovery curve declines, a surge in demand is likely. As compute becomes more accurate and accessible, the pharma industry will likely move toward a world where simulating every protein and molecule becomes a standard part of research.
The current pharmaceutical landscape reflects a shift toward immediate utility, where companies are bypassing the wait for a perfect quantum computer in favour of building a hybrid reality. In this model, supercomputers manage vast information (handling datasets and data processing), while today’s quantum processors handle the precise biological interactions that traditional systems find impossible. This can be seen in the AI factories being built by Eli Lilly and Roche, paired with quantum partnerships like AstraZeneca’s recent work with IonQ.
The impact of quantum technology extends beyond the research lab to diagnostics too. Quantum sensors can offer precision by monitoring signals of a single cell to spot the earliest markers of cancer or neurological change years before they would ever appear on a traditional MRI. When combined with quantum algorithms that can process an entire genetic profile in minutes, healthcare shifts to a highly targeted, patient-specific model.
The evolution of healthcare will likely be defined by the convergence of three distinct technologies, each with a unique role: Generative AI, which excels at scanning massive datasets to identify potential drug candidates or genetic markers based on existing data; Agentic AI, which allows for automation of clinical workflows and removing administrative friction from hospitals; Quantum computing, which simulates the complex physical interactions of the patterns recognised by AI with a high level of accuracy.
The integration of quantum technology can transform healthcare into a model based on predictive precision. It allows the industry to move toward a model where research is more efficient and diagnostic tools are significantly more accurate. The convergence of AI and quantum computing does more than just lower the cost of innovation, it provides the healthcare industry with the tools to address the root causes of disease with molecular-level clarity. Ultimately, this move toward a digital-first framework creates an opportunity for healthcare that is more personalised, proactive, and capable of addressing the most complex challenges in human biology.